About Ipriflavone
A synthetic isoflavone derivative studied for osteoporosis. A large multicenter RCT (Alexandersen 2001, JAMA) found 600 mg/day did not prevent bone loss and caused lymphopenia in some subjects. Not recommended as effective for bone health. ⚠️ Inhibits CYP1A2 and can raise levels of theophylline, caffeine, and other CYP1A2 substrates.
What Ipriflavone supports
- Synthetic isoflavone studied for bone (negative RCT)
How much Ipriflavone to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
200–600
mg
Bone trials used 200 mg three times daily (600 mg/day).
Clinical evidence
Limited clinical evidence. Large RCT found no bone benefit and a lymphopenia safety signal
Reference